Cargando…
Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis
Bisphosphonates are one of the most widely used synthetic pyrophosphate analogues for the treatment of bone resorbing diseases such as osteoporosis, multiple myeloma, and bone metastases. Although the therapeutic usefulness of bisphosphonates mainly depends on their anti-osteoclastogenic effect, a s...
Autores principales: | Kim, Hyung Joon, Kim, Ha Jin, Choi, YunJeong, Bae, Moon-Kyoung, Hwang, Dae Seok, Shin, Sang-Hun, Lee, Jae-Yeol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471260/ https://www.ncbi.nlm.nih.gov/pubmed/30909508 http://dx.doi.org/10.3390/ijms20061467 |
Ejemplares similares
-
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
por: Wijenayaka, Asiri R., et al.
Publicado: (2011) -
TNF-α Directly Enhances Osteocyte RANKL Expression and Promotes Osteoclast Formation
por: Marahleh, Aseel, et al.
Publicado: (2019) -
Calcium-Phosphate Crystals Promote RANKL Expression via the Downregulation of DUSP1
por: Choi, YunJeong, et al.
Publicado: (2019) -
Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone
por: Xiong, Jinhu, et al.
Publicado: (2015) -
Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation
por: Miyagawa, Kazuaki, et al.
Publicado: (2023)